DE60141827D1 - Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und -differenzierung - Google Patents

Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und -differenzierung

Info

Publication number
DE60141827D1
DE60141827D1 DE60141827T DE60141827T DE60141827D1 DE 60141827 D1 DE60141827 D1 DE 60141827D1 DE 60141827 T DE60141827 T DE 60141827T DE 60141827 T DE60141827 T DE 60141827T DE 60141827 D1 DE60141827 D1 DE 60141827D1
Authority
DE
Germany
Prior art keywords
muscle
increase
muscle mass
acrp30
differentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141827T
Other languages
English (en)
Inventor
Harvey Lodish
Joachim Fruebis
Tsu-Shuen Tsao
Bernard Bihain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Whitehead Institute for Biomedical Research
Original Assignee
Serono Genetics Institute SA
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Genetics Institute SA, Whitehead Institute for Biomedical Research filed Critical Serono Genetics Institute SA
Application granted granted Critical
Publication of DE60141827D1 publication Critical patent/DE60141827D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60141827T 2000-05-31 2001-05-22 Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und -differenzierung Expired - Lifetime DE60141827D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20825100P 2000-05-31 2000-05-31
US23973500P 2000-10-11 2000-10-11
PCT/IB2001/001126 WO2001092330A2 (en) 2000-05-31 2001-05-22 Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation

Publications (1)

Publication Number Publication Date
DE60141827D1 true DE60141827D1 (de) 2010-05-27

Family

ID=26903041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141827T Expired - Lifetime DE60141827D1 (de) 2000-05-31 2001-05-22 Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und -differenzierung

Country Status (9)

Country Link
US (2) US7405193B2 (de)
EP (1) EP1294866B1 (de)
JP (1) JP2003535104A (de)
AT (1) ATE464378T1 (de)
AU (2) AU781253B2 (de)
CA (1) CA2410758A1 (de)
DE (1) DE60141827D1 (de)
IL (2) IL153200A0 (de)
WO (1) WO2001092330A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288223A1 (en) * 2002-05-17 2005-12-29 Genset S.A. OBG3 Fragments Inhibiting The Conversion Of Active OBG3 Into Less Active OBG3 And Other Compositions For Treatment Of Metabolic Disorders
WO2004083432A1 (en) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
EP2167135A2 (de) * 2007-07-12 2010-03-31 Prosensa Technologies B.V. Moleküle für targeting von verbindungen auf verschiedene ausgewählte organe, gewebe oder tumorzellen
CN103212085A (zh) * 2007-07-12 2013-07-24 普罗森那技术公司 用于使化合物靶向多种选定器官或组织的分子
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
EP2088156A1 (de) 2008-02-08 2009-08-12 Institut Pasteur Verwendung von Adiponektin zur Diagnose und/oder Behandlung von Presbyakusis
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
JP2012524540A (ja) 2009-04-24 2012-10-18 プロセンサ テクノロジーズ ビー．ブイ． Ｄｍｄを処置するためのイノシンを含むオリゴヌクレオチド
AU2010335039B2 (en) 2009-12-24 2015-03-26 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Molecule for treating an inflammatory disorder
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
KR101438744B1 (ko) * 2012-08-02 2014-09-15 전남대학교산학협력단 아디포넥틴을 유효성분으로 포함하는 안구건조증 또는 염증성 안구표면 질환의 예방 또는 치료용 조성물
JP6539511B2 (ja) * 2015-06-17 2019-07-03 花王株式会社 運動機能の判定用マーカー
NL2015032B1 (en) 2015-06-26 2017-01-24 Vitalnext B V Compositions and methods for the treatment of malnutrition.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869330A (en) * 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
WO1999021577A1 (fr) * 1997-10-29 1999-05-06 Otsuka Pharmaceutical Co., Ltd. Compositions inhibant la proliferation des muscles lisses, procede de diagnostic de l'arteriosclerose et trousses correspondantes
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US6579852B2 (en) 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en) 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
MXPA02006834A (es) * 2000-01-14 2005-07-01 Genset Sa Extremo anterior de obg3 globular y usos del mismo para disminuir la masa corporal.
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
EP1355657A2 (de) 2001-02-02 2003-10-29 Genset Gssp3 polynucleotide und polypeptide und deren verwendung
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
AU2002339686B2 (en) 2001-10-12 2007-12-20 Serono Genetics Institute S.A. NGZIPA, NGZIPD, PGZIPA, and PGZIPD polynucleotides and polypeptides and uses thereof

Also Published As

Publication number Publication date
US7405193B2 (en) 2008-07-29
IL153200A0 (en) 2003-07-06
AU781253B2 (en) 2005-05-12
EP1294866B1 (de) 2010-04-14
JP2003535104A (ja) 2003-11-25
AU7439801A (en) 2001-12-11
US20060035824A1 (en) 2006-02-16
US20080274971A1 (en) 2008-11-06
AU2005203365B2 (en) 2008-02-14
EP1294866A2 (de) 2003-03-26
ATE464378T1 (de) 2010-04-15
AU2005203365A1 (en) 2005-08-25
CA2410758A1 (en) 2001-12-06
WO2001092330A2 (en) 2001-12-06
IL153200A (en) 2010-05-17
WO2001092330A3 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
DE60141827D1 (de) Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und -differenzierung
ATE305296T1 (de) Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung
DE69909775D1 (de) Neue fettanaloge zur behandlung von diabetes
ATE395052T1 (de) Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
ATE356113T1 (de) Probucolbernsteinsäureester zur hemmung der expression von vcam-1
BR0012748A (pt) Análogo super-ativo do hormÈnio de lberação do hormõnio do crescimento porcino
ATE342964T1 (de) Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen
GEP20053660B (en) Novel Tyrosine Kinase Inhibitors
TW200519202A (en) Modulation of eIF4E expression
TW200502385A (en) Modulation of forkhead box o1a expression
ATE321525T1 (de) Verwendung von konjugierten linolensaüren zur topischen behandlung von zellulitis
MY123177A (en) Protein composition and process for isolating a protein composition from a muscle source
EA200201214A1 (ru) Замещенные тиоацетамиды
ATE330608T1 (de) Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60307237D1 (de) Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
DE60216281D1 (de) Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
EA200100583A1 (ru) Композиции, содержащие лактадгерин или его варианты, и способы их использования
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
ATE322244T1 (de) Verwendung von polyaminosäurederivaten zur behandlung von seborrhoe und verwandten hautstörungen
IL157495A0 (en) Method for the production of d-panthothenic acid and/or salts thereof as adjunct for animal feedstuffs
ATE218334T1 (de) Verwendung von gabapentin in der behandlung vonangst - und panikstörungen
DE60224064D1 (de) Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition